Role of beta-blockers in patients admitted for worsening heart failure in a real world setting: data from the Italian Survey on Acute Heart Failure
1 ANMCO Research Center, Via La Marmora 34, 50121 Florence, Italy
2 Department of Critical Care Medicine and Surgery, Section of Geriatric Medicine, University School of Medicine, Florence, Italy
3 Ospedale Villa Malta, Department of Cardiology, Sarno (SA), Italy
4 Ospedale Civile, Department of Cardiology, Lugo (RA), Italy
5 Ospedale San Leopoldo Mandic, Department of Cardiology, Merate (LC), Italy
6 Ospedale Castelli, Department of Cardiology, Verbania (VB), Italy
7 IRCCS Policlinico S. Matteo, Department of Cardiology, Pavia, Italy
* Corresponding author. Tel: +39 055 5101361, Fax: +39 055 5101310, Email: maggioni{at}anmco.it
 |
Abstract |
|---|
Aims: Randomized trials have shown that beta-blockers (BBs) reduce mortality in chronic heart failure (HF). Less data are available on the role of BBs in patients with acute HF, specifically if BBs should be continued or temporarily withdrawn. The aim of this study was to evaluate the role of BBs on in-hospital outcomes of patients admitted for worsening HF in a Cardiology setting.
Methods and results: One thousand five hundred and seventy-two patients enrolled in the Italian Survey on Acute HF were evaluated. According to the BB therapy before and during hospitalization, four groups were defined: group A, no/no (51.6%); group B, no/yes (16.4%); group C, yes/no (9.0%); and group D, yes/yes (23.0%). Groups B and D had a significantly lower in-hospital mortality rate (group B 1.2%, group D 2.8%, group A 10.1%, and group C 12.1%; P < 0.0001). The association between non-use or withdrawal of BBs and higher mortality rate was confirmed by the multivariable analysis [group D, reference group; odds ratio (OR) 3.28, 95% confidence interval (CI) 1.47–7.32 and OR 4.20, 95% CI 1.59–11.10 for groups A and C, respectively], whereas no difference was found between groups B and D (OR 0.34, 95% CI 0.07–1.78).
Conclusion: In patients hospitalized for worsening HF, non-use or discontinuation of BBs was associated with a significant higher mortality.
Key Words: Beta-blockers • Prognosis • Acute heart failure
Received March 29, 2008; Revised July 11, 2008; Accepted September 1, 2008
The complete list of the Italian Survey on Acute Heart Failure Investigators has been already published as Appendix of ref 14.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Jondeau, Y. Neuder, J.-C. Eicher, P. Jourdain, E. Fauveau, M. Galinier, A. Jegou, F. Bauer, J. N. Trochu, A. Bouzamondo, et al. B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode Eur. Heart J., September 2, 2009; 30(18): 2186 - 2192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G.F. Cleland, A. P. Coletta, A. Torabi, and A. L. Clark Clinical trials update from the European Society of Cardiology heart failure meeting 2009: CHANCE, B-Convinced, CHAT, CIBIS-ELD, and Signal-HF Eur J Heart Fail, August 1, 2009; 11(8): 802 - 805. [Abstract] [Full Text] [PDF]
|
|